
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
36.13 US$
−0.05 US$ · -0.14%
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
الإغلاق السابق
36.13 US$
−0.05 US$ · -0.14%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
نطاق اليوم
السعر الحالي 36.13 US$
نطاق 52 أسبوعًا
السعر الحالي 36.13 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
73
أقل من القيمة
المشاعر
63
صعودي
المخاطر
44
مخاطر أعلى من المعتاد
الزخم
74
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
نطاق اليوم
السعر الحالي 36.13 US$
نطاق 52 أسبوعًا
السعر الحالي 36.13 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 225.21 مليون USD | 187.34 مليون USD | 159.01 مليون USD | 138.58 مليون USD | 127.36 مليون USD |
| تكلفة البضاعة المباعة | 57.86 مليون USD | 45.36 مليون USD | 37.14 مليون USD | 29.78 مليون USD | 22.93 مليون USD |
| الربح الإجمالي | 167.35 مليون USD | 141.98 مليون USD | 121.87 مليون USD | 108.81 مليون USD | 104.43 مليون USD |
| البحث والتطوير | 32.89 مليون USD | 27.77 مليون USD | 27.34 مليون USD | 25.63 مليون USD | 24.18 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 142.32 مليون USD | 117.5 مليون USD | 115.99 مليون USD | 112.89 مليون USD | 105.67 مليون USD |
| نفقات التشغيل | 175.2 مليون USD | 145.26 مليون USD | 143.33 مليون USD | 138.52 مليون USD | 129.84 مليون USD |
| مصاريف الفوائد | 7.7 مليون USD | 8.21 مليون USD | 2.84 مليون USD | 624 ألف USD | 1.36 مليون USD |
| الاستهلاك والإطفاء | 8.19 مليون USD | 7.84 مليون USD | 5.55 مليون USD | 4.85 مليون USD | 4.74 مليون USD |
| الدخل التشغيلي | −7.85 مليون USD | −3.29 مليون USD | −21.46 مليون USD | −29.71 مليون USD | −25.42 مليون USD |
| صافي الدخل | −15.7 مليون USD | −9.96 مليون USD | −21.72 مليون USD | −28.95 مليون USD | −26.99 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
توزيعات نقدية سنوية معدلة للسهم الواحد.
1.00 US$
2010 سنة كاملة+2296.8% منذ 1992
0.0417 US$
1,992
0.06 US$
2,005
1.00 US$
2,010
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباح | 27 يناير 2010 | 1.00 US$Special | 29 يناير 2010 | 12 فبراير 2010 |
توزيعات الأرباح | 23 فبراير 2005 | 0.06 US$Special | — | — |
توزيعات الأرباح | 10 يوليو 1992 | 0.0417 US$Special | — | — |
استحقاق التوزيعات 27 يناير 2010
1.00 US$
Special
تاريخ التسجيل 29 يناير 2010 · تاريخ الدفع 12 فبراير 2010
استحقاق التوزيعات 23 فبراير 2005
0.06 US$
Special
استحقاق التوزيعات 10 يوليو 1992
0.0417 US$
Special
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI81.24 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM50.79 مليون0.06%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF31.38 مليون0.03%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO17.67 مليون0.13%13.92 مليار USD0.24%356.78 US$+0.94%
Vanguard Russell 2000 ETFVTWO15.36 مليون0.08%18 مليار USD0.06%112.66 US$+0.50%
Schwab U.S. Small-Cap ETFSCHA11.24 مليون0.05%21.82 مليار USD0.03%32.79 US$+0.40%
Fidelity Enhanced Small Cap ETFFESM11.04 مليون0.17%6.41 مليار USD0.28%45.46 US$+0.46%
iShares U.S. Medical Devices ETFIHI10.5 مليون0.30%3.57 مليار USD0.37%51.74 US$+1.25%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESM
iShares U.S. Medical Devices ETFIHIالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.